Bruce C.  Cozadd net worth and biography

Bruce Cozadd Biography and Net Worth

Bruce C. Cozadd brings extensive experience in research and development, manufacturing and sales and marketing. After being inspired by the culture at ALZA where he started his career, Mr. Cozadd wanted to start a company where top talent can do their best and work inclusively as a team. It was under these ideals that Mr. Cozadd co-founded Jazz Pharmaceuticals Inc. in 2003.

Mr. Cozadd co-founded Jazz Pharmaceuticals, Inc. in 2003 and has served as our Chairman and Chief Executive Officer since April 2009. From 1991 until 2001, he held various positions with ALZA Corporation, a pharmaceutical company acquired by Johnson & Johnson, most recently as Executive Vice President and Chief Operating Officer, with responsibility for research and development, manufacturing and sales and marketing. Previously at ALZA Corporation he held the roles of Chief Financial Officer and Vice President, Corporate Planning and Analysis. Mr. Cozadd serves on the board of Biotechnology Innovation Organization (BIO), a biotechnology trade association, where he serves on its Health Section Governing Board. Mr. Cozadd also serves on the boards of two non-profit organizations, The Nueva School and SFJAZZ. He received a B.S. from Yale University with a double major in molecular biophysics and biochemistry and economics and an M.B.A. from the Stanford Graduate School of Business.

What is Bruce C. Cozadd's net worth?

The estimated net worth of Bruce C. Cozadd is at least $40.04 million as of February 1st, 2023. Mr. Cozadd owns 367,078 shares of Jazz Pharmaceuticals stock worth more than $40,040,868 as of April 26th. This net worth evaluation does not reflect any other assets that Mr. Cozadd may own. Additionally, Mr. Cozadd receives a salary of $2,450,000.00 as CEO at Jazz Pharmaceuticals. Learn More about Bruce C. Cozadd's net worth.

How old is Bruce C. Cozadd?

Mr. Cozadd is currently 60 years old. There are 6 older executives and no younger executives at Jazz Pharmaceuticals. Learn More on Bruce C. Cozadd's age.

What is Bruce C. Cozadd's salary?

As the CEO of Jazz Pharmaceuticals plc, Mr. Cozadd earns $2,450,000.00 per year. Learn More on Bruce C. Cozadd's salary.

How do I contact Bruce C. Cozadd?

The corporate mailing address for Mr. Cozadd and other Jazz Pharmaceuticals executives is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. Jazz Pharmaceuticals can also be reached via phone at (531) 634-7800 and via email at [email protected]. Learn More on Bruce C. Cozadd's contact information.

Has Bruce C. Cozadd been buying or selling shares of Jazz Pharmaceuticals?

Bruce C. Cozadd has not been actively trading shares of Jazz Pharmaceuticals over the course of the past ninety days. Most recently, Bruce C. Cozadd sold 1,000 shares of the business's stock in a transaction on Wednesday, February 1st. The shares were sold at an average price of $155.79, for a transaction totalling $155,790.00. Following the completion of the sale, the chief executive officer now directly owns 367,078 shares of the company's stock, valued at $57,187,081.62. Learn More on Bruce C. Cozadd's trading history.

Who are Jazz Pharmaceuticals' active insiders?

Jazz Pharmaceuticals' insider roster includes Paul Berns (Director), Patricia Carr (SVP), Jennifer Cook (Director), Bruce Cozadd (CEO), Patrick Enright (Director), Renée Galá (CFO), Peter Gray (Director), Robert Iannone (EVP), Finbar Larkin (SVP), Seamus Mulligan (Director), Kenneth O'Keefe (Director), Anne Oriordan (Director), Neena Patil (Insider), Samantha Pearce (SVP), Kim Sablich (EVP), Elmar Schnee (Director), Mark Smith (Director), Christopher Tovey (COO), and Rick Winningham (Director). Learn More on Jazz Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Jazz Pharmaceuticals?

During the last year, Jazz Pharmaceuticals insiders bought shares 1 times. They purchased a total of 12,000 shares worth more than $1,435,800.00. During the last year, insiders at the specialty pharmaceutical company sold shares 10 times. They sold a total of 13,870 shares worth more than $1,827,470.63. The most recent insider tranaction occured on March, 6th when CAO Patricia Carr sold 1,936 shares worth more than $231,623.04. Insiders at Jazz Pharmaceuticals own 4.4% of the company. Learn More about insider trades at Jazz Pharmaceuticals.

Information on this page was last updated on 3/6/2024.

Bruce C. Cozadd Insider Trading History at Jazz Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/1/2023Sell1,000$155.79$155,790.00367,078View SEC Filing Icon  
1/3/2023Sell3,000$159.86$479,580.00368,078View SEC Filing Icon  
12/1/2022Sell1,000$157.00$157,000.00371,078View SEC Filing Icon  
11/10/2022Sell2,000$150.00$300,000.00372,028View SEC Filing Icon  
10/3/2022Sell45,185$134.93$6,096,812.05374,028View SEC Filing Icon  
9/6/2022Sell7,703$153.18$1,179,945.54353,311View SEC Filing Icon  
8/1/2022Sell7,301$154.31$1,126,617.31354,311View SEC Filing Icon  
7/5/2022Sell8,775$157.28$1,380,132.00351,912View SEC Filing Icon  
6/1/2022Sell6,362$146.87$934,386.94351,987View SEC Filing Icon  
5/2/2022Sell7,260$156.63$1,137,133.80348,502View SEC Filing Icon  
4/4/2022Sell10,772$158.33$1,705,530.76346,062View SEC Filing Icon  
2/1/2022Sell6,372$139.23$887,173.56View SEC Filing Icon  
12/1/2021Sell6,748$122.66$827,709.68View SEC Filing Icon  
11/1/2021Sell6,556$134.75$883,421.00View SEC Filing Icon  
10/4/2021Sell6,598$129.87$856,882.26View SEC Filing Icon  
8/2/2021Sell1,750$169.98$297,465.00307,388View SEC Filing Icon  
7/1/2021Sell10,850$180.67$1,960,269.50308,888View SEC Filing Icon  
5/5/2021Sell500$170.00$85,000.00321,841View SEC Filing Icon  
5/3/2021Sell1,500$164.24$246,360.00321,841View SEC Filing Icon  
4/1/2021Sell1,500$164.96$247,440.00323,341View SEC Filing Icon  
2/3/2021Sell1,500$156.79$235,185.00
1/4/2021Sell7,950$162.01$1,287,979.50319,532View SEC Filing Icon  
12/3/2020Sell250$150.00$37,500.00View SEC Filing Icon  
12/1/2020Sell1,000$140.58$140,580.00View SEC Filing Icon  
11/2/2020Sell1,000$145.13$145,130.00331,180View SEC Filing Icon  
10/1/2020Sell4,500$141.94$638,730.00332,180View SEC Filing Icon  
9/1/2020Sell500$134.90$67,450.00336,680View SEC Filing Icon  
8/27/2020Sell3,000$130.00$390,000.00View SEC Filing Icon  
1/2/2020Sell1,250$149.61$187,012.50300,138View SEC Filing Icon  
12/2/2019Sell10,750$150.00$1,612,500.00View SEC Filing Icon  
11/5/2019Sell500$130.00$65,000.00311,855View SEC Filing Icon  
10/1/2019Sell500$130.00$65,000.00View SEC Filing Icon  
11/1/2018Sell1,300$159.45$207,285.00278,615View SEC Filing Icon  
10/1/2018Sell1,300$167.99$218,387.00279,915View SEC Filing Icon  
9/21/2018Sell1,300$164.36$213,668.00281,215View SEC Filing Icon  
8/1/2018Sell1,600$173.90$278,240.00282,515View SEC Filing Icon  
7/2/2018Sell1,600$170.81$273,296.00284,115View SEC Filing Icon  
6/1/2018Sell7,000$168.86$1,182,020.00View SEC Filing Icon  
5/1/2018Sell1,000$151.57$151,570.00View SEC Filing Icon  
4/2/2018Sell1,000$150.01$150,010.00293,542View SEC Filing Icon  
3/9/2018Sell1,000$150.00$150,000.00294,542View SEC Filing Icon  
2/28/2018Sell1,000$150.00$150,000.00267,468View SEC Filing Icon  
1/12/2018Sell3,000$150.00$450,000.00View SEC Filing Icon  
10/2/2017Sell1,000$150.00$150,000.00View SEC Filing Icon  
9/12/2017Sell1,000$153.52$153,520.00View SEC Filing Icon  
5/11/2017Sell30,000$153.47$4,604,100.00296,418View SEC Filing Icon  
4/11/2017Sell1,000$152.12$152,120.00308,491View SEC Filing Icon  
8/9/2016Sell1,000$150.00$150,000.00View SEC Filing Icon  
3/8/2016Sell2,500$126.04$315,100.00302,566View SEC Filing Icon  
2/9/2016Sell2,500$111.37$278,425.00281,896View SEC Filing Icon  
1/12/2016Sell2,500$123.81$309,525.00284,396View SEC Filing Icon  
12/8/2015Sell2,500$139.72$349,300.00286,855View SEC Filing Icon  
11/10/2015Sell2,500$128.53$321,325.00289,355View SEC Filing Icon  
10/13/2015Sell2,500$131.50$328,750.00291,855View SEC Filing Icon  
9/8/2015Sell2,500$163.07$407,675.00294,355View SEC Filing Icon  
7/14/2015Sell5,000$177.79$888,950.00View SEC Filing Icon  
6/9/2015Sell5,000$173.16$865,800.00View SEC Filing Icon  
4/14/2015Sell5,000$181.45$907,250.00View SEC Filing Icon  
12/9/2014Sell5,000$178.79$893,950.00View SEC Filing Icon  
9/9/2014Sell5,000$170.32$851,600.00View SEC Filing Icon  
8/12/2014Sell5,000$133.15$665,750.00View SEC Filing Icon  
7/8/2014Sell5,000$155.00$775,000.00View SEC Filing Icon  
6/10/2014Sell5,000$142.34$711,700.00View SEC Filing Icon  
See Full Table

Bruce C. Cozadd Buying and Selling Activity at Jazz Pharmaceuticals

This chart shows Bruce C Cozadd's buying and selling at Jazz Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Jazz Pharmaceuticals Company Overview

Jazz Pharmaceuticals logo
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $109.08
Low: $106.73
High: $109.16

50 Day Range

MA: $118.60
Low: $107.10
High: $132.77

2 Week Range

Now: $109.08
Low: $106.61
High: $146.70

Volume

135,246 shs

Average Volume

600,021 shs

Market Capitalization

$6.87 billion

P/E Ratio

17.82

Dividend Yield

N/A

Beta

0.59